Novo Nordisk raised its full-year sales and profit outlook, expecting a smaller decline than previously forecasted, driven by strong GLP-1 product sales including the Wegovy pill. However, analysts remain cautious as the better-than-expected quarter was partly due to temporary rebate adjustments, and obesity drug sales were mostly in line with expectations. The company also reported disappointing clinical results for its next-generation weight-loss drug CagriSema, raising concerns about its long-term pipeline. Intense competition from Eli Lilly's newer obesity drugs continues to pressure Novo Nordisk's market position, leaving investors uncertain about sustainable growth prospects.
Novo Nordisk's U.S.-traded shares dropped over 5% after the company raised its 2026 sales and profit outlook but projected adjusted sales and operating profit to decline up to 6% or remain flat at constant exchange rates. The company reported a 3% ri...
Citi maintained a neutral rating on Novo Nordisk following the failure of its heart drug ziltevekimab in the ZEUS trial, which showed no benefit over placebo in reducing cardiovascular events. Despite this setback, the drug's expected peak sales are ...
Citi maintains a neutral rating on Novo Nordisk after its anti-inflammatory drug ziltevekimab failed to meet the primary endpoint in a heart disease trial. The trial showed no significant benefit over placebo and raised safety concerns. While Citi vi...
SpaceX will release its first public earnings report focusing on Starlink's growth, Starship development, and capital spending. Despite shares falling over 50% from their peak and trading below the IPO price, Wall Street remains optimistic with bulli...
As employers increasingly drop insurance coverage for GLP-1 weight-loss drugs like Wegovy and Zepbound, major retailers such as Walmart, Costco, CVS, and Amazon are expanding direct-to-consumer prescription programs to capture market share. These pro...
